Apports et limites des modeles precliniques pour le developpement des associations de chimiotherapies anticancereuses

In chemosensitive tumors, cancer chemotherapy is active as drug combinations. During the development of new anticancer drugs, preclinical experimental models may help to design drug combinations. Indeed, in vitro models are able to define drug interactions in terms of synergism, additivity or antagonism, while in vivo models can evaluate therapeutic synergism along with toxicity in a clinical setting. The methodology for in vitro and in vivo evaluation of anticancer drug combinations is described. The limits are discussed. In conclusion, preclinical models contribute to the clinical development of drug combinations which are nevertheless designed on the basis of clinical therapeutic principles.